Stemnovate and Babraham Institute come together to untangle the tauopathy in Alzheimer’s disease

Stemnovate and Babraham Institute come together to untangle the tauopathy in Alzheimer’s disease

Stemnovate and Babraham Institute come together to untangle the tauopathy in Alzheimer’s disease

Key points:

  • A Babraham Research Campus collaboration fund is supporting an exciting project that unites expertise in cellular reprogramming and the cellular process of autophagy to explore the role of this process in the development of Alzheimer's Disease.
  • Researchers from Babraham Research Campus company Stemnovate will collaborate with senior group leader Dr Nick Ktistakis.
  • The project aims to uncover a better understanding of the connection between autophagy and neurodegeneration, creating a cell-based model that can be used to identify new targets for drug development.


An exciting research collaboration ‘sprint’ is getting ready to launch on the Babraham Research Campus to better understand the role of an essential cellular process in brain health.

A pump-priming collaboration grant to the Babraham Research Campus-based company Stemnovate Ltd. and Dr Nick Ktistakis from the Babraham Institute will support a proof-of-principle project to understand how the cellular quality control process of autophagy targets protein aggregates in the brain. Using blood or skin samples from volunteer donors, the research project will look to provide an important piece in the puzzle to determine how autophagy is important for brain health. 

Autophagy is a process of nutrient recycling and elimination of unnecessary or damaged cellular material in cells, leading to a periodic clean-up of the cell interior and recycling of nutrients during times of low resources.

The suppression of autophagy and the subsequent build-up of aggregated proteins may be one causative agent for neurodegenerative disorders such as Alzheimer's Disease and the project will explore the role of protein aggregation in Alzheimer's, known as a tauopathy.

Both located on the Babraham Research Campus, Stemnovate will use its expertise in controlling cell identity through cellular reprogramming and cellular differentiation, plus experience of working with donated patient samples, to produce neuronal cell lines for analysis by the Ktistakis lab. Dr Nick Ktistakis’s research focuses on understanding autophagy in healthy cells and in the context of diseases.

Dr Ruchi Sharma, CEO of Stemnovate, said, "The tau protein is a potential treatment target for Alzheimer’s and understanding its role may improve the age-related physiological decline. Moreover, the novel cellular modelling helps us understand the devastating condition that has already affected millions of people in our ageing population.”

Dr Nick Ktistakis, senior group leader at the Babraham Institute and an expert on the autophagy process, said, "We are very excited to take advantage of this opportunity to work in partnership with Stemnovate and to apply our autophagy assays and cutting-edge imaging analysis to better understand the connection between autophagy and neurodegeneration."

The risk of dementia increases with age, with an estimated frequency of one in 14 people over the age of 65 being affected, which increases to one in every six people over the age of 80 (source: NHS1). According to Alzheimer’s Research UK, approximately six out of every 10 cases of dementia is due to Alzheimer’s2. In addition to the personal toll dementia takes on lives, the economic cost of dementia in the UK in 2021 was estimated to be £25 billion, with these costs expected to rise to £47 billion in 2050 (source: Dementia Statistics Hub, Alzheimer’s Research UK3).

Dr Ktistakis outlined their hopes for the project’s outcomes: “If we can discover when and how autophagy acts to prevent protein aggregates forming then this will identify targets that can be assessed as therapeutic candidates to enhance good protein clearance. In itself, the model we will develop through this joint work can be used in the future to further understand neurodegeneration and identify potential treatments.”

The research collaboration will work with samples donated from people diagnosed with Alzheimer’s Disease. Dr Sharma explained: “We are asking members of the public to get involved with this research by donating a blood sample or a small skin sample from which we can obtain the cells needed for our research. We know the impact that this disease has on individuals and families and we hope that we can make an important contribution, alongside other research efforts, to improve our understanding of this disease.”

People interested in finding out more about donating samples to the study can contact Stemnovate on

Dr Kathryn Chapman, Director of Science and Entrepreneurship at the Babraham Research Campus, who oversees the Babraham Research Campus funding programme that will support this project, said: “We’re passionate about making the Campus the best place to start and grow a life science venture. By supporting early stage discovery through connecting innovation across academic research and commercial research we are accelerating the delivery of knowledge and tools that will make a real-world difference. The collaboration between Stemnovate and the Institute is a perfect demonstration of this impact and I can’t wait to see where it will lead.”


Notes to Editors

Referenced sources:

1          NHS information on Alzheimer’s Disease obtained from

2          Alzheimer’s Research UK - What is Alzheimer’s disease?

3          Dementia Statistics Hub, Alzheimer’s Research UK

Press contact

Dr Louisa Wood, Head of Communications,

Image description

The background image shows induced pluripotent stem cell-derived neuronal cells stained with neuronal antibodies (red). The two panels show cells from an immortalised human cell line (HEK293) growing in control conditions (left) or induced for autophagy (right). Staining is for autophagy proteins.

About Stemnovate

Stemnovate’s vision is to apply their pioneering platform for targeted drug development to make personalised medicine a global reality, ensuring efficient drug discovery, diagnostics and targeted treatments. Our mission is to accelerate drug discovery from decades to years and from months to days. Visit Stemnovate's website to find out more.

About the Babraham Institute

The Babraham Institute undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through Institute Strategic Programme Grants and an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.

About Babraham Research Campus Limited

Babraham Research Campus Ltd is responsible for the management and commercial development of the Babraham Research Campus. Babraham Research Campus is distinct in its co‐location of 60 bioscience companies with the Babraham Institute, a world‐renowned research organisation which receives strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC). The aim of the Campus is to support UK bioscience through academic research, but also with facilities and capabilities for early-stage and growing commercial organisations. The Campus provides companies laboratory and office space, networking and collaboration opportunities, together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

For more information please visit: and follow the Campus on Twitter @BabrahamUK.


The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.

BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by government, BBSRC invested £451 million in world-class bioscience in 2019-20. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.